Fresenius

Fresenius – the Health Care Group

Fresenius is a health care group with products and services for dialysis, the hospitalization and patient medical care. In addition, Fresenius focuses on hospital operations as well as on engineering and services for hospitals. More than 110,000 employees work with dedication in the service of health in around 100 countries of the globe.

The Fresenius Group consists of the four business segments Fresenius Medical Care, Fresenius Kabi and Fresenius Helios and Fresenius Vamed.

Fresenius Medical Care

Fresenius Medical Care is the world's leading provider of products and services for patients with chronic kidney failure.

With a network of 2,238 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care treats 173,863 dialysis patients around the world (as of December 31, 2007).

Fresenius Kabi

Fresenius Kabi is the leader in Infusion Therapy and Clinical Nutrition in Europe. In the growth regions of Asia-Pacific and Latin America, the company has a leading position in nearly all of its markets.

Fresenius Kabi provides treatment and care for critically-ill patients in both the hospital and out-patient environments. With a corporate philosophy of "Caring for Life," the company’s goal is to improve the patient's quality of life.

To the homepage of Fresenius Kabi


Fresenius Kabi provides:

• Infusion Therapy
• Parenteral Nutrition
• Enteral Nutrition
• Infusion Technology
• Transfusion Technology
• Ambulatory Care

Fresenius Kabi is a subsidiary of Fresenius SE and employs more than 16,000 people worldwide. It has a global network of roundabout 50 sales and marketing organizations and 35 production sites.

Fresenius Kabi's factory in Friedberg, Germany, is one of the most modern European plants for the production of standard infusion solutions. Fresenius Kabi also has established a highly automated production site for parenteral nutrition infusion solutions in Uppsala, Sweden.

Fresenius HELIOS

The HELIOS Hospital Group ranks among the largest and most medically-advanced hospital groups in Europe. It specializes in hospital management with a focus on acute treatment and subsequent medical rehabilitation.

The private hospital group owns 60 clinics including five maximum care hospitals in Erfurt, Berlin-Buch, Wuppertal, Schwerin and Krefeld. HELIOS is headquartered in Berlin and employs 30,000 people.

The HELIOS Hospital Group provides expertise in all areas and at all levels of clinical care, including maximum care. The Group comprises HELIOS Kliniken GmbH, specializing in acute medicine, and Wittgensteiner Kliniken GmbH, which focuses on rehabilitation.

HELIOS is committed to delivering excellence in clinical and nursing care. The Group provides high quality, state-of-the-art medical care which makes a significant contribution to the advancement of medical science. HELIOS offers the most advanced and verifiably best diagnosis and treatment methods, to the benefit of patients. The HELIOS Research Center coordinates and funds clinical research within the company in cooperation with the Max Delbrück Center for Molecular Medicine (MDC), the Berlin Charité University Hospital and the University of Witten-Herdecke. Nine HELIOS hospitals are teaching hospitals through academic partnerships with universities.

To the homepage of HELIOS Hospital Group.

Further information in English can be found here.


 

Fresenius VAMED

VAMED operates in the project and management business of health care facilities worldwide. These include hospitals and health care centers as well as spas and wellness centers. The company headquartered in Vienna, Austria, has 1,800 of its own employees and is responsible for more than 6,000 employees including all projects worldwide. VAMED has completed approximately 450 health care projects in 47 countries since its foundation in 1982.

In line with its own "from one source" philosophy, VAMED offers the following services for health care facilities:

• Project development
• Planning
• Project management
• Turnkey hospital projects
• Complete medical equipment
• Service and maintenance of medical-technical installations
• Facility management
• Technical management
• General management

To the homepage of VAMED

Fresenius Biotech

Fresenius Biotech GmbH is a company of the Fresenius health care group, focused on the development and marketing of biopharmaceuticals in the fields of oncology and immunology/transplantation medicine. The company also holds a majority interest in the European Institute for Research and Development of Transplantation Strategies (EUFETS AG).

The business activities of Fresenius Biotech are:

• Immunosuppression in organ transplantation
• Development of trifunctional antibodies for cancer treatment
• Manufacturing of products for cell and gene therapy (EUFETS)

Immunosuppression in organ transplantation

Fresenius Biotech is manufacturing and commercializing an immunosuppressive agent, a polyclonal antibody that is used in organ transplantation. This medicinal product has been proven to be effective in suppressing the rejection of organs by the immune system. Currently, the efficacy and safety of this immunosuppressant are being assessed in clinical trials for bone marrow transplantation and stem cell transplantation.

Development of trifunctional antibodies for cancer treatment

This innovative therapy with trifunctional antibodies activates the immune system to destroy tumor cells. Currently, clinical studies are investigating the antibodies for use against various tumors. Possible therapeutic options for future applications of the antibodies could be an adjuvant setting (after surgical resection of a tumor) or as additional immune therapy after previous chemo- or radiation therapy. Fresenius Biotech has successfully completed several clinical studies. Trifunctional antibodies are a development of our partner TRION Pharma.

Clinical Studies with Trifunctional Antibodies (PDF, 54 KB)

Manufacturing of products for cell and gene therapy

The European Institute for Research and Development of Transplantation Strategies (EUFETS AG) is a competence center for gene and cell therapy where Fresenius holds a majority interest. EUFETS can offer a comprehensive know how for the development and production of cell therapeutics, retroviral vectors and the genetic modification of primary cells or cell lines. The services include a broad spectrum ranging from process development and validation up to the production of material for clinical trials as well as for the market. In addition, EUFETS can provide cell-based in vitro safety and efficacy studies under GLP conditions as well as support of clinical studies.

Company Profile (PDF, 123 KB)

Capital Market Day Presentations, 15.1.2004

Glossary (PDF, 116 KB)